A Phase 1 interventional study of 13-valent Pneumococcal Conjugate Vaccine and 13-valent Pneumococcal Conjugate Vaccine in Pneumococcal Infection, sponsored by Pfizer. Completed at 2 sites in China. Open to participants aged 42 Days to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-09-07.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
This study will assess the safety and tolerability of a single dose of 13-valent Pneumococcal Conjugate Vaccine for approximately 1 month after vaccination sequentially in healthy Chinese adults aged 18 through 55 years, followed by children aged 3 through 5 years, and then infants aged approximately 2 months.
281 studies on the registry are indexed under Pneumococcal Infections; 27 are open to participants now.
This study's enrollment of 72 is below the median of 379 across 230 interventional studies indexed under Pneumococcal Infections.
Browse Pneumococcal Infections studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Age at the time of enrollment is:
Exclusion Criteria:
Adults aged 18 through 55 years (before the fifty sixth birthday)
Biological: 13-valent Pneumococcal Conjugate Vaccine
Children aged 3 through 5 years (before the sixth birthday)
Biological: 13-valent Pneumococcal Conjugate Vaccine
Infants aged approximately 2 months (42 to 98 days)
Biological: 13-valent Pneumococcal Conjugate Vaccine
suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
Number of participants reporting Adverse Events
Time frame: Baseline to Month 1
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer